Welcome : Guest

NantKwest, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about NantKwest, Inc., which is principally a Clinical-Stage Immunotherapy Company. Illustrated with 58 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-66214
Price: $2900
Company Type: Public
Pages: 61
Date: January 2017
Market Data Tables: 58

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: NantKwest, Inc.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, Europe, and Other Non-U.S......2
Immunotherapy......5
Table 2: No. of Patients for Immunotherapy by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Europe, North America, and Others......5
Table 3: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......6
Table 4: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......7
Table 5: No. of Patients for Immunotherapy by Age Group in the US (2015) - Percentage Market Share Breakdown by Value for 0-4 Patient Pool, 10 - 14 Patient Pool, 15 - 19 Patient Pool, 5-9 Patient Pool, Adult Patient Pool (over 65), and Adult Patient Pool (under 65)......8
Cancer Drugs......9
Table 6: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......9
Table 7: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......10
Cancer Market......11
Table 8: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......11
Table 9: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......12
Table 10: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......13
Table 11: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......14
Table 12: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......15
Table 13: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......16
Table 14: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......17
Cancer Patients......18
Table 15: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
Table 16: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......19
Table 17: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......20
Table 18: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......21
Table 19: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......22
Table 20: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......23
Table 21: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......24
Table 22: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......25
Table 23: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......26
Table 24: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......27
Table 25: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......28
Table 26: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......29
Table 27: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......30
Table 28: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......31
Cervical Cancer......32
Table 29: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......32
Table 30: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......33
Hematological Cancer......34
Table 31: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......34
Skin Cancer......35
Table 32: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......35
Cancer-Associated Mucositis......36
Table 33: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......36
Multiple Myeloma......37
Table 34: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......37
Table 35: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......38
Non Hodgkin lymphoma (NHL)......39
Table 36: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......39
Table 37: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Volume for Burkitt Lymphoma-Burkitt Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Immunodeficiency-Associated Lymphoproliferative Disorders, Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma, Small Cell Lymphocytic Lymphoma-Chronic Lymphocytic Leukemia, T-Cell and Natural Killer (NK) -Cell Lymphoma, and Others......40
Table 38: Indolent Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......41
Table 39: No. of Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......42
Table 40: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......43
Table 41: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......44
Table 42: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......45
Table 43: No. of Non Hodgkin lymphoma (NHL) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......46
Table 44: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......47
Table 45: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......48
Table 46: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......49
Infectious Disease Drugs......50
Table 47: Infectious Disease Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Molecular Diagnostics Infectious Diseases, and Others......50
Table 48: Infectious Disease Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antifungals, Antivirals, Cephalosporins, Macrolides, Penicillins, Quinolones, and Others......51
Cancer Drugs......52
Table 49: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......52
Table 50: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......53
Table 51: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......54
Table 52: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......55
Table 53: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......56
Breast Cancer Drugs......57
Table 54: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......57
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......58
Table 55: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Other......58
Table 56: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Other......59
Infectious Disease Drugs......60
Table 57: Market Shares of Leading Infectious Disease Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol- Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......60
Table 58: NovoCure Ltd.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, and Europe, Israel and Japan......61